Overview

Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma

Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore feasibility of Upper Tract Urothelial Carcinoma (UTUC) treatments based in real world data in various European countries. The study will allow to gain insight in the true proportion of patients that fit to receive complete cisplatin-based neo-adjuvant or adjuvant chemotherapy, and the proportion and clinical outcome of patients with poor prognostic factors (PS and renal function) who receive only standard treatment (Radical nephroureterectomy (RNU)). This comparison will be made using a uniform diagnostic and treatment protocol.
Phase:
Phase 2
Details
Lead Sponsor:
The European Uro-Oncology Group
Collaborator:
Centre for Human Drug Research, Netherlands
Treatments:
Cisplatin
Cyclophosphamide
Dactinomycin
Doxorubicin
Gemcitabine
Methotrexate
Vinblastine
Vincristine